$APLS
Apellis Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023017819 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $94.97M $44.85M $14.38M
YoY Change 481.85% 211.84%
Cost Of Revenue $8.379M $7.809M $1.247M
YoY Change 10118.29% 526.22%
Gross Profit $86.59M $37.04M $13.13M
YoY Change 433.19% 181.99%
Gross Profit Margin 91.18% 82.59% 91.33%
Selling, General & Admin $111.4M $102.1M $88.95M
YoY Change 8.83% 14.78% 36.63%
% of Gross Profit 128.62% 275.65% 677.22%
Research & Development $95.66M $110.0M $90.95M
YoY Change -5.9% 20.98% 8.25%
% of Gross Profit 110.47% 297.07% 692.44%
Depreciation & Amortization $425.0K $421.0K $377.0K
YoY Change 10.1% 11.67% 33.69%
% of Gross Profit 0.49% 1.14% 2.87%
Operating Expenses $207.0M $219.9M $143.4M
YoY Change 25.51% 53.39% 15.08%
Operating Profit -$120.4M -$175.1M -$129.0M
YoY Change -18.96% 35.73% 3.54%
Interest Expense -$1.339M -$2.136M -$8.440M
YoY Change -80.92% -74.69% -60.0%
% of Operating Profit
Other Income/Expense, Net -$63.00K -$277.0K -$289.0K
YoY Change -142.28% -4.15% -118.72%
Pretax Income -$121.8M -$177.5M -$137.7M
YoY Change -21.64% 28.88% -25.01%
Income Tax $194.0K $300.0K $1.200M
% Of Pretax Income
Net Earnings -$122.0M -$177.8M -$138.9M
YoY Change -21.76% 27.96% -24.35%
Net Earnings / Revenue -128.5% -396.42% -966.1%
Basic Earnings Per Share -$1.02 -$1.56 -$1.42
Diluted Earnings Per Share -$1.02 -$1.56 -$1.417M
COMMON SHARES
Basic Shares Outstanding 116.5M 111.3M 98.07K
Diluted Shares Outstanding 119.3K 113.9K 98.07K

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $616.3M $765.1M $965.3M
YoY Change -27.74% -20.74% 33.38%
Cash & Equivalents $616.3M $765.1M $633.5M
Short-Term Investments $331.8M
Other Short-Term Assets $44.91M $34.35M $73.41M
YoY Change 57.81% -53.21% 46.82%
Inventory $103.2M $85.48M $32.85M
Prepaid Expenses $34.40M $36.56M $24.53M
Receivables $110.9M $31.50M $6.300M
Other Receivables $17.39M $0.00 $0.00
Total Short-Term Assets $892.7M $954.3M $1.104B
YoY Change -7.01% -13.56% 42.71%
LONG-TERM ASSETS
Property, Plant & Equipment $22.07M $5.967M $5.893M
YoY Change 274.49% 1.26% -16.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $827.0K $793.0K $16.01M
YoY Change -94.79% -95.05% 131.68%
Total Long-Term Assets $22.89M $24.61M $41.87M
YoY Change -46.17% -41.22% 14.63%
TOTAL ASSETS
Total Short-Term Assets $892.7M $954.3M $1.104B
Total Long-Term Assets $22.89M $24.61M $41.87M
Total Assets $915.6M $978.9M $1.146B
YoY Change -8.67% -14.57% 41.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.50M $31.49M $12.27M
YoY Change 69.54% 156.61% 195.17%
Accrued Expenses $103.6M $71.25M $105.3M
YoY Change 15.82% -32.32% 51.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $43.77M $30.07M $2.664M
YoY Change 176.28% 1028.79% -57.03%
Total Short-Term Liabilities $174.8M $138.6M $124.8M
YoY Change 37.89% 11.12% 49.12%
LONG-TERM LIABILITIES
Long-Term Debt $382.8M $414.5M $541.0M
YoY Change -26.8% -23.37% 40.07%
Other Long-Term Liabilities $12.50M $347.0K $1.208M
YoY Change 696.37% -71.27% -99.58%
Total Long-Term Liabilities $395.3M $347.0K $1.208M
YoY Change 25096.81% -71.27% -99.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $174.8M $138.6M $124.8M
Total Long-Term Liabilities $395.3M $347.0K $1.208M
Total Liabilities $570.2M $566.7M $683.6M
YoY Change -14.65% -17.1% -9.87%
SHAREHOLDERS EQUITY
Retained Earnings -$2.600B -$2.500B -$1.796B
YoY Change 33.22% 39.23% 64.13%
Common Stock $12.00K $12.00K $11.00K
YoY Change 9.09% 9.09% 37.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $345.4M $412.1M $462.2M
YoY Change
Total Liabilities & Shareholders Equity $915.6M $978.9M $1.146B
YoY Change -8.67% -14.57% 41.44%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$122.0M -$177.8M -$138.9M
YoY Change -21.76% 27.96% -24.35%
Depreciation, Depletion And Amortization $425.0K $421.0K $377.0K
YoY Change 10.1% 11.67% 33.69%
Cash From Operating Activities -$150.2M -$177.6M -$111.6M
YoY Change 40.3% 59.21% -27.23%
INVESTING ACTIVITIES
Capital Expenditures $372.0K $259.0K $86.00K
YoY Change -195.14% 201.16% -82.23%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$271.9M
YoY Change -100.0% -100.0% 85.85%
Cash From Investing Activities -$372.0K -$259.0K -$271.9M
YoY Change -100.45% -99.9% 85.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $380.1M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.560M 391.1M 376.7M
YoY Change -132.95% 3.82% 22982.35%
NET CHANGE
Cash From Operating Activities -150.2M -177.6M -111.6M
Cash From Investing Activities -372.0K -259.0K -271.9M
Cash From Financing Activities 1.560M 391.1M 376.7M
Net Change In Cash -149.0M 213.3M -6.741M
YoY Change 416.71% -3263.97% -97.75%
FREE CASH FLOW
Cash From Operating Activities -$150.2M -$177.6M -$111.6M
Capital Expenditures $372.0K $259.0K $86.00K
Free Cash Flow -$150.5M -$177.9M -$111.6M
YoY Change 41.16% 59.32% -27.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001492422
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38276
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
APELLIS PHARMACEUTICALS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1537290
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Fifth Avenue
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
977-5700
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
APLS
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
116457008
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
765083000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
551801000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31505000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7727000
CY2023Q1 us-gaap Inventory Net
InventoryNet
85484000
CY2022Q4 us-gaap Inventory Net
InventoryNet
85714000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36559000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36350000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
1275000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1273000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
34349000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
36658000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
954255000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
719523000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17854000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18747000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5967000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6148000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
793000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15799000
CY2023Q1 us-gaap Assets
Assets
978869000
CY2022Q4 us-gaap Assets
Assets
760217000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
31494000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
37342000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
71251000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95139000
CY2023Q1 apls Development Liability Current
DevelopmentLiabilityCurrent
30071000
CY2022Q4 apls Development Liability Current
DevelopmentLiabilityCurrent
29504000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5828000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5625000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
138644000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
167610000
CY2023Q1 apls Development Liability Noncurrent
DevelopmentLiabilityNoncurrent
321713000
CY2022Q4 apls Development Liability Noncurrent
DevelopmentLiabilityNoncurrent
315647000
CY2023Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
92809000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
92736000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13233000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14352000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
347000
CY2023Q1 us-gaap Liabilities
Liabilities
566746000
CY2022Q4 us-gaap Liabilities
Liabilities
590345000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116179000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116179000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110772000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110772000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2899524000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2479596000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-775000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-875000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2486638000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2308860000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
412123000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
169872000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
978869000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
760217000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44846000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14381000
CY2023Q1 apls Operating Cost Of Sales
OperatingCostOfSales
7809000
CY2022Q1 apls Operating Cost Of Sales
OperatingCostOfSales
1247000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
110027000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90945000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
102093000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51187000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
219929000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
143379000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-175083000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-128998000
CY2023Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
5393000
CY2022Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
98000
CY2023Q1 apls Interest Expense Nonoperating
InterestExpenseNonoperating
7529000
CY2022Q1 apls Interest Expense Nonoperating
InterestExpenseNonoperating
8538000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-277000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-289000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-177496000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-137727000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
282000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1208000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-177778000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-138935000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
100000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
83000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
100000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
31000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-177678000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-138904000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113872
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113872
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98069
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98069
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
169872000
CY2023Q1 apls Issuance Of Common Stock And Pre Funded Warrants In Common Stock Offering
IssuanceOfCommonStockAndPreFundedWarrantsInCommonStockOffering
384387000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17718000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-10999000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28823000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-177778000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
100000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
412123000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
198662000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
380120000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2416000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20773000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-138935000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
83000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
462235000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-177778000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-138935000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
28823000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
20773000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-19000
CY2023Q1 apls Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal
OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal
-22000
CY2022Q1 apls Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal
OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal
-17000
CY2023Q1 us-gaap Depreciation
Depreciation
421000
CY2022Q1 us-gaap Depreciation
Depreciation
377000
CY2023Q1 apls Amortization Of Discounts For Convertible Notes Net Of Financing Costs
AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts
73000
CY2022Q1 apls Amortization Of Discounts For Convertible Notes Net Of Financing Costs
AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts
144000
CY2023Q1 apls Accretion Of Discount To Development Liability
AccretionOfDiscountToDevelopmentLiability
6633000
CY2022Q1 apls Accretion Of Discount To Development Liability
AccretionOfDiscountToDevelopmentLiability
6713000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1208000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
23778000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3773000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-144000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
16533000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
107000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-334000
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2308000
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2312000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-14969000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15634000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5854000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6371000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-23471000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3652000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-177620000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111560000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
259000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
331863000
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
60000000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-259000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-271949000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
380120000
CY2023Q1 apls Proceeds From Issuance Of Common Stock And Pre Funded Warrant Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantOfferingNetOfIssuanceCosts
384387000
CY2022Q1 apls Payments For Development Liability
PaymentsForDevelopmentLiability
5000000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17718000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
10999000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2416000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
391106000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
376704000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
213283000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6741000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
553075000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
641755000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
766358000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
635014000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
765083000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
633456000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1275000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
1558000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
766358000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
635014000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1643000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
3360000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
250000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of Organization and Operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Apellis Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company’s principal executive offices are located in Waltham, Massachusetts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital, developing its product candidates, commercializing EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (“PNH”) and the commercializing of SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy secondary to age-related macular degeneration (“GA).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> From inception to March 31, 2023, the Company has incurred cash outflows from operations, losses from operations and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion primarily as a result of expenses incurred through a combination of research and development activities related to our various product candidates and expenses supporting those activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of May 4, 2023, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">765.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of March 31, 2023 combined with its cash flows generated from sales will be sufficient to fund its operations and capital expenditures for at least the next twelve months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s future viability beyond that point is dependent on its ability to achieve commercial success for SYFOVRE and EMPAVELI. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are uncertainties associated with the Company’s ability to (1) obtain additional debt or equity financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed.</span></p>
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2500000000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
765100000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: development liability, accrued expenses, prepaid expenses, convertible debt and taxes.</span></p>
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31500000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7700000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
300000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
300000
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
33948000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
29847000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
48471000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
54101000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3065000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1766000
CY2023Q1 us-gaap Inventory Net
InventoryNet
85484000
CY2022Q4 us-gaap Inventory Net
InventoryNet
85714000
CY2023Q1 apls Down Payments For Inventory Current
DownPaymentsForInventoryCurrent
7649000
CY2022Q4 apls Down Payments For Inventory Current
DownPaymentsForInventoryCurrent
13987000
CY2023Q1 apls Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
16469000
CY2022Q4 apls Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
15181000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
12441000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7182000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36559000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36350000
CY2023Q1 apls Royalties Receivable Current
RoyaltiesReceivableCurrent
1597000
CY2022Q4 apls Royalties Receivable Current
RoyaltiesReceivableCurrent
1442000
CY2023Q1 apls Employee Retention Credit Current
EmployeeRetentionCreditCurrent
8711000
CY2022Q4 apls Employee Retention Credit Current
EmployeeRetentionCreditCurrent
8711000
CY2023Q1 apls Receivable From Collaboration Agreement Current
ReceivableFromCollaborationAgreementCurrent
15000000
CY2022Q4 apls Receivable From Collaboration Agreement Current
ReceivableFromCollaborationAgreementCurrent
20000000
CY2023Q1 apls Deposits And Other Current Assets
DepositsAndOtherCurrentAssets
9041000
CY2022Q4 apls Deposits And Other Current Assets
DepositsAndOtherCurrentAssets
6505000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
34349000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
36658000
CY2023Q1 apls Maximum Number Of Employees With Employers Eligible For Refundable Tax Credit
MaximumNumberOfEmployeesWithEmployersEligibleForRefundableTaxCredit
500
CY2021 apls Percentage Of Qualified Wages Paid To Employees Under Employee Retention Credit
PercentageOfQualifiedWagesPaidToEmployeesUnderEmployeeRetentionCredit
0.70
CY2021Q3 apls Maximum Credit Per Employee For Each Calendar Quarter
MaximumCreditPerEmployeeForEachCalendarQuarter
7000
CY2022Q4 apls Refund Filed Under Cares Act Relating To Employee Retention Credit
RefundFiledUnderCaresActRelatingToEmployeeRetentionCredit
8700000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M25D
CY2023Q1 apls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
31510000
CY2022Q4 apls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
34849000
CY2023Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1558000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
907000
CY2023Q1 apls Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
24189000
CY2022Q4 apls Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
43212000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13994000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16171000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
71251000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95139000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M2D
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2465000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3286000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3286000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
96225000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
105262000
CY2023Q1 us-gaap Longterm Debt Percentage Bearing Fixed Interest Amount
LongtermDebtPercentageBearingFixedInterestAmount
11365000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1088000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
92809000
CY2023Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many of these leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases.
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q1 apls Lessee Operating Lease Maximum Term Of Options To Terminate Lease
LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease
P1Y
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17854000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18747000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
19061000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
19977000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0722
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0726
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1700000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1400000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2022000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1669000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5206000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6319000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5151000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4299000
CY2023Q1 apls Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
556000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
21531000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2470000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
19061000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1200000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 apls Minimum Percentage Of Tax Position Likelihood Of Being Realized Upon Examination By Taxing Authorities
MinimumPercentageOfTaxPositionLikelihoodOfBeingRealizedUponExaminationByTaxingAuthorities
0.50
CY2023Q1 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19145000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21264000

Files In Submission

Name View Source Status
apls-20230331_cal.xml Edgar Link unprocessable
apls-20230331_pre.xml Edgar Link unprocessable
0000950170-23-017819-index-headers.html Edgar Link pending
0000950170-23-017819-index.html Edgar Link pending
0000950170-23-017819.txt Edgar Link pending
0000950170-23-017819-xbrl.zip Edgar Link pending
apls-20230331.htm Edgar Link pending
apls-20230331.xsd Edgar Link pending
apls-ex31_1.htm Edgar Link pending
apls-ex31_2.htm Edgar Link pending
apls-ex32_1.htm Edgar Link pending
apls-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
apls-20230331_def.xml Edgar Link unprocessable
apls-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apls-20230331_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending